黑料福利社

We are advancing a diversified pipeline with the potential to make a meaningful difference for patients with cancer who have no or few alternative treatment options. Our current pipeline of investigational DDR-targeting medicines includes two clinical-stage assets, alnodesertib and ART6043, and the preclinical DDRi-ADC program, ART21934.

 

Clinical Development Strategy

Our clinical development strategy is built on six core pillars designed to maximize each program鈥檚 probability of success. What differentiates our approach is:

 

1. Optimized Therapeutic Index
Through disciplined target selection, iterative molecular design, and rigorous clinical dose optimization, our approach to achieving an optimal therapeutic index is grounded in decades of hands-on experience developing DDR-targeted molecules and a precise understanding of where earlier-generation compounds fell short.

2. Rational Development Strategy
We seek to further enhance the potential efficacy of our drug candidates through rational combination strategies with known and approved DNA-damaging therapies, such as chemotherapy and radioligand therapies (RLTs), and through attaching our DDRi candidates to monoclonal antibodies to create novel ADCs.

3. Precision Patient Selection
We leverage a deep understanding of DDR biology to identify patient populations and treatment settings most likely to benefit from our therapies.

4. Clinical Positioning
We evaluate clinical positioning across therapy lines and tumor types to identify treatment settings where our product candidates may address significant unmet medical needs, ultimately leading to greater long-term survival relative to existing treatment options.

5. Proprietary DDR Chemistry and Biology Platform
Our proprietary expertise in DDR biology and medicinal chemistry underpins our product candidates.

6. Broad Tumor-Type Expansion Across the Portfolio
Our development strategy is designed to extend each program beyond its initial indication into a range of additional solid tumor types where the underlying biology supports therapeutic benefit.

 

The six core pillars are applied consistently across all our programs, creating a scalable and differentiated approach to advancing next-generation DDR-targeted therapies.

Our lead clinical candidate, alnodesertib (formerly known as ART0380), is an oral, highly selective small molecule inhibitor of ataxia telangiectasia and Rad3-related protein (ATR) with first-in-class potential. It is designed to exert anti-tumor activity in cancers that harbor high levels of endogenous replication stress using ATM protein deficiency as an initial biomarker. ATM-deficient tumors exhibit impaired DNA repair and higher levels of DNA replication stress, creating selective vulnerabilities to DDR-targeted therapies like alnodesertib. It is further optimized for use in combination with a DNA-damaging therapy such as chemotherapy, to enhance anti-tumor activity and improve patient outcomes.

Mechanism of Action

ATR is a critical signaling protein kinase that helps cells respond to DNA damage and enables cancer cells to survive replication stress. It helps to stabilize the replication fork, the epicenter of DNA replication, and initiates DNA break repair, enabling subsequent cell division. Ataxia-telangiectasia mutated (ATM) is a complementary DDR kinase that helps cells sense DNA damage, coordinate checkpoint signaling, and orchestrate the repair of DNA double-strand breaks to preserve genome integrity. In ATM-deficient tumors, that protective layer is weakened, so cells become more reliant on ATR-mediated signaling pathways to maintain their survival under conditions of replication stress.

As depicted in the figure, in ATM-deficient solid tumors, endogenous replication stress (RS) can be further exacerbated by DNA-damaging chemotherapy, increasing their reliance on ATR to manage RS. ATR inhibition with alnodesertib is designed to overwhelm this compensatory pathway, resulting in replication fork collapse, DNA double-strand breaks, mitotic catastrophe, and cancer cell death.

Clinical Development of alnodesertib

Alnodesertib, in combination with a low subtherapeutic dose of chemotherapy, irinotecan, is currently being evaluated in two Phase 2 expansion cohorts for the treatment of patients with colorectal and pancreatic cancer in an ATM biomarker-driven patient population.

In our Phase 1/2 study, the drug appeared to be well-tolerated when alnodesertib was combined with the low dose of irinotecan. We observed tumor responses across 10 different cancer types when biomarker testing of the patient鈥檚 tumor revealed the absence or near absence of ATM.

Alnodesertib in combination with low-dose irinotecan has received U.S. FDA Fast Track designation for the treatment of adult patients with ATM-negative metastatic colorectal cancer who were previously administered certain current therapies.

For more information, please click .

---

Our second clinical asset, ART6043, is a selective, orally bioavailable, small molecule inhibitor of the polymerase domain of DNA polymerase theta (Pol胃). Pol胃 is a DNA repair enzyme that is expressed in cancer cells but is virtually absent in most healthy tissues. ART6043 is designed to amplify the impact of DNA double-strand breaks when used in combination with PARP inhibitors, a first-generation DDR therapy.

Mechanism of Action

Cancer cells rely heavily on Pol胃 as a backup DNA repair mechanism to survive when their primary DNA repair pathway is defective or when they acquire resistance to DNA-damaging therapies such as PARP inhibitors. Pol胃 plays a key role in repairing DNA double-strand breaks during the cell cycle and when other repair mechanisms such as homologous recombination (HR) or non-homologous end joining (NHEJ) are compromised or overwhelmed. Mutations in genes such as BRCA1 and BRCA2, result in the inherent impairment of HR pathways, leading to the accumulation of replication- and damage-associated DNA breaks. In this context, Pol胃 becomes a key dependency, rescuing stalled replication forks and promoting DNA replication restart, which enables tumor cells to continue dividing.

Inhibiting Pol胃 in BRCA1/2-mutant or other HR-deficient cancers exacerbates unresolved DNA breaks, increases chromosomal aberrations, and triggers cell death, while normal cells with intact HR remain relatively unperturbed. ART6043 is specifically designed to further enhance DNA damage in combination with PARP inhibition by creating additional double-strand DNA breaks, thereby increasing cancer cell killing. Pol胃 inhibition is also hypothesized to prevent the emergence of resistance to PARP inhibitors by suppressing BRCA reversions.

Clinical Development of ART6043

ART6043 is currently being evaluated in the randomized Phase 2 POLKA study in combination with an approved dose of the PARP inhibitor (PARPi), olaparib, versus olaparib alone in patients with PARPi-na茂ve, gBRCAm, HER2-negative metastatic breast cancer who are eligible to receive a PARPi.

ART6043 demonstrated expected Pharmacokinetic/Pharmacodynamic activity, promising clinical signals in the Phase 1/2a study, and no serious adverse events deemed to be study-related were reported.

ART6043 received FDA Fast Track designation for the treatment of germline BRCA-mutated human epidermal growth factor receptor HER2-negative patients with locally advanced or metastatic breast cancer who have received no prior treatment with a PARPi.

黑料福利社 is also exploring the potential of Pol胃 with DNA damaging agents such as chemotherapies, ionizing radiation and radioligand therapy as well as with immuno-oncology medicines.

For more information, please click .

---

Our first product candidate from the DDRi-antibody drug conjugate (ADC) platform, ART21934, is rationally designed to address a large and growing population of patients with solid tumors that become resistant to TOP1 inhibitor-based ADCs and have limited treatment options. Our highly differentiated DDRi-ADC platform is designed to broaden the reach and impact of DDR targeting across oncology through novel DDRi payloads in defined patient populations.

Mechanism of Action

ART21934 is a TROP2-targeting ADC with a novel payload mechanism that, as demonstrated in preclinical studies, can 鈥渓ock鈥� PARP onto chromatin for an extended period of time. Locked PARP obstructs normal DNA processes, causing toxic DNA double-strand breaks and eventual cell death.

Clinical Development of ART21934

We are advancing our lead DDRi- ADC candidate, ART21934, through IND-enabling studies. Robust preclinical proof-of-concept has been established in a range of TOP1i-ADC-resistant models, with activity also demonstrated in Elahere庐-resistant tumor models and PARPi-resistant tumor models.

黑料福利社 is a clinical-stage company focused on developing novel anti-cancer therapies that target DNA Damage Response (DDR) pathways. We are committed to developing transformational DDR-based therapeutics to patients with solid tumors.

Clinical trials are designed to evaluate the safety and effectiveness of product candidates. By participating in these trials, patients can access investigational treatments, including 黑料福利社’ product candidates before they receive approval from a country鈥檚 regulatory authorities. Access to 黑料福利社鈥� investigational product candidates is currently limited to controlled clinical trials. For information regarding 黑料福利社-sponsored clinical trials, please visit and search for 黑料福利社.

In certain situations, when it is not possible for a patient to participate in a clinical trial due to serious or immediately life-threatening conditions and no other treatment options are available, their doctor may request special access to investigational product candidates outside of a clinical trial. This is known as expanded access. 黑料福利社 does not currently offer an expanded access program; this statement will be updated and further information provided if this policy is amended.